O omalizumabe no tratamento da urticária no contexto da pandemia de COVID-19
Omalizumab as urticaria treatment in the context of the COVID-19 pandemic
Luis Felipe Ensina; Sérgio Duarte Dortas-Junior; Rosana Câmara Agondi; Faradiba Sarquis Serpa; Solange Oliveira Rodrigues Valle; Roberta Fachini Jardim Criado; Joanemile Pacheco de-Figueiredo; Juliano Coelho Philippi; Fernanda Lugão Campinhos; Chayanne Andrade de-Araújo; Luisa Karla Arruda
Resumo
O início da pandemia de COVID-19 foi marcado por incertezas diante do desconhecimento sobre a doença. Uma série de dúvidas relacionadas ao uso de imunobiológicos no contexto da pandemia foi levantada, inclusive em relação ao tratamento com omalizumabe em pacientes com urticária crônica (UC). Este estudo teve como objetivo analisar os dados relacionados à gravidade da COVID-19 e a evolução da urticária em pacientes em terapia com omalizumabe acompanhados por especialistas no Brasil. Foi realizada análise retrospectiva de dados de pacientes com UC tratados com omalizumabe entre julho/2020 e junho/2021 que apresentaram COVID-19. Foram avaliados dados relacionados às características clínicas dos pacientes e evolução da urticária durante a infecção pelo SARS-CoV2. Foram incluídos 28 pacientes em tratamento com omalizumabe, sendo 27 com urticária crônica espontânea (UCE), dos quais 25% tinham alguma urticária induzida associada. A maior parte dos pacientes (71%) estavam utilizando doses quadruplicadas de anti-histamínicos modernos de 2ª geração associados ao omalizumabe. Todos os pacientes estavam com os sintomas controlados. Entre os sintomas apresentados durante a COVID-19, os mais frequentes foram: febre (43%), cefaleia (36%), mal-estar (32%), hipo/anosmia (29%) e tosse (21%). Quatro pacientes foram hospitalizados, um deles em unidade de terapia intensiva. Um paciente relatou piora dos sintomas da UC durante a COVID-19. Cinco (18%) pacientes apresentaram piora dos sintomas da UC após a resolução da COVID-19. Todos os pacientes se recuperaram da COVID-19 sem sequelas graves. O OMA não pareceu aumentar o risco de COVID-19 grave e poderia ser usado com segurança em pacientes com UC.
Palavras-chave
Abstract
The beginning of the COVID-19 pandemic was marked by uncertainty due to lack of knowledge about the disease. Questions were raised about the use of immunobiologicals in the pandemic context, including omalizumab for patients with chronic urticaria (UC). This study assessed COVID-19 severity and the clinical course of urticaria in Brazilian patients on omalizumab therapy who were monitored by specialists. We retrospectively analyzed data from chronic urticaria patients treated with omalizumab between July, 2020 and June, 2021 who presented with COVID19. Clinical characteristics and the course of urticaria during SARS-CoV2 infection were analyzed. The sample consisted of 28 patients treated with omalizumab, 27 of whom had chronic spontaneous urticaria (UCE) and 25% of whom had associated chronic inducible urticaria. Most of the patients (71%) were using quadruple doses of second-generation antihistamines associated with omalizumab. The symptoms of all patients were controlled. The most frequent symptoms during COVID-19 were: fever (43%), headache (36%), malaise (32%), hypo/anosmia (29%) and cough (21%). Four patients were hospitalized, including 1 in intensive care. One patient reported worsening chronic urticaria symptoms while infected with COVID-19. Five (18%) patients experienced worsening chronic urticaria symptoms after recovery from COVID-19. All patients recovered from COVID-19 without serious sequelae. Omalizumab did not appear to increase the risk of severe COVID-19 and can be safely used in patients with chronic urticaria.
Keywords
References
1. Dortas-Junior SD, Azizi GG, Bastos-Junior RM, Brum CRMA, Tavares JVV, et al. Urticária e COVID-19: foco nesta manifestação clínica. Arq Asma Alerg Imunol. 2021;5:100-3.
2. World Health Organization (WHO). Novel Coronavirus (2019- nCoV) [Internet]. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Acessado em: 27/03/2023.
3. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13:1833-9.
4. Vultaggio A, Agache I, Akdis CA, Akdis M, Bavbek S, Bossios A, et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Allergy. 2020;75:2764-74.
5. Maurer M, Church MK, Gonçalo M, Sussman G, Sanchez-Borges M. Management and treatment of chronic urticaria (CU). JEADV. 2015;29(Suppl 3):16-32.
6. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer- Weber B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393-414.
7. Gill MA, Liu AH, Calatroni A, Krouse RZ, Shao B, Schiltz A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141:1735-43.
8. Cardet JC, Casale TB. New insights into the utility of omalizumab. J Allergy Clin Immunol. 2019;143:923-6.
9. Criado PR, Pagliari C, Criado RFJ, Marques GF, Belda W Jr. What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Dermatol Ther. 2020;33:e14068.
10. Ensina LF, Valle SOR, Juliani AP, Galeane M, Santos RV dos, Arruda LK, et al. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience. Int Arch Allergy Imm. 2016;169:121-4.
11. Imbalzano E, Casciaro M, Quartuccio S, Minciullo PL, Cascio A, Calapai G, et al. Association between urticaria and virus infections: A systematic review. Allergy Asthma Proc. 2016;37:18-22.
12. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e212-13.
13. Bostan E, Zaid F, Karaduman A, Dogan S, Gulseren D, Yalici- Armagan B, et al. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study. J Cosmet Dermatol. 2021;20:3369-75.
14. Muntean IA, Pintea I, Bocsan IC, Dobrican CT, Deleanu D. COVID-19 Disease Leading to Chronic Spontaneous Urticaria Exacerbation: A Romanian Retrospective Study. Healthcare (Basel). 2021;9:1144.
15. Passante M, Napolitano M, Dastoli S, Bennardo L, Fabbrocini G, Nisticò SP, et al. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Dermatol Ther. 2021;34:e15111.
16. Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, Peter J, Comert-Ozer E, et al. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2021;76:816-30.
17. Ayhan E, Öztürk M, An I, Bekçlbasi M. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases. Int J Dermatol. 2021;60:253-4.
18. Paulino M, Costa C, Pedro E. Omalizumab treatment during SARSCoV- 2 infection. COVID-19 Pandemic: Case Studies & Opinions. 2020;1:153-4.
Submitted date:
03/20/2023
Accepted date:
04/18/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email